ERBB2 and breast carcinoma: We evaluated both the prognostic role of HER2 overexpression and its potential role as a modifier of the effect of adjuvant therapy in a population of early breast cancer patients enrolled in a phase III study comparing two epirubicin-containing regimens with different dose densities.